Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T
Open Access
- 7 March 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 112 (6), 562-573
- https://doi.org/10.1093/jnci/djaa021
Abstract
Sipuleucel-T is an autologous cellular immunotherapy that induces an immune response targeted against prostatic acid phosphatase (PAP) to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. In the phase III IMPACT study, sipuleucel-T was associated with a statistically significantly increased overall survival (OS) (median = 4.1 months) vs placebo. Patients with baseline prostate-specific antigen levels in the lowest quartile (≤22.1 ng/mL) exhibited a 13-month improvement in OS with sipuleucel-T. Together, this led sipuleucel-T to be approved and recommended as first-line therapy in various guidelines for treatment of metastatic castration-resistant prostate cancer. This review discusses the varied findings about the mechanisms of action of sipuleucel-T, bringing them together to form a more coherent picture. These pieces include inducing a statistically significant increase in antigen-presenting cell activation; inducing a peripheral immune response specific to the target (PAP) and/or immunizing (PA2024) antigens; stimulating systemic cytotoxic T-lymphocyte activity; and mediating antigen spread (ie, increased antibody responses to secondary proteins in addition to PAP and PA2024). Each of these pieces individually correlates with OS. Sipuleucel-T also traffics T cells to the prostate and is associated with long-term immune memory such that a second course of treatment induces an anamnestic immune response. Prostate cancer does not have a strongly inflamed microenvironment, thus its response to immune checkpoint inhibitors is limited. Because sipuleucel-T is able to traffic T cells to the tumor, it may be an ideal combination partner with immunotherapies including immune checkpoint inhibitors or with radiation therapy.Funding Information
- Dendreon Pharmaceuticals LLC
This publication has 90 references indexed in Scilit:
- Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African DescentProstate Cancer, 2013
- Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancerCancer Immunology, Immunotherapy, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Therapeutic Cancer Vaccines: Current Status and Moving ForwardJNCI Journal of the National Cancer Institute, 2012
- Prostate Cancer ImmunotherapyClinical Cancer Research, 2011
- Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further ResearchClinical Cancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010
- Prostate‐specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate‐targeted PSA/KLK2 double transgenic miceThe Prostate, 2010